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Purpose: To investigate the relationship between early treatment response to definitive chemoradiotherapy (CRT) and survival 
outcome in patients with limited stage small cell lung cancer (LS-SCLC).
Materials and Methods: We retrospectively reviewed 47 patients with LS-SCLC who received definitive CRT between January 
2009 and December 2012. Patients were treated with systemic chemotherapy regimen of etoposide/carboplatin (n = 15) or 
etoposide/cisplatin (n = 32) and concurrent thoracic radiotherapy at a median dose of 54 Gy (range, 46 to 64 Gy). Early treatment 
volume reduction rate (ETVRR) was defined as the percentage change in gross tumor volume between diagnostic computed 
tomography (CT) and simulation CT for adaptive RT planning and was used as a parameter for early treatment response. The median 
dose at adaptive RT planning was 36 Gy (range, 30 to 43 Gy), and adaptive CT was performed in 30 patients (63.8%).
Results: With a median follow-up of 27.7 months (range, 5.9 to 75.8 months), the 2-year locoregional progression-free survival 
(LRPFS) and overall survival (OS) rates were 74.2% and 56.5%, respectively. The mean diagnostic and adaptive gross tumor volumes 
were 117.9 mL (range, 5.9 to 447 mL) and 36.8 mL (range, 0.3 to 230.6 mL), respectively. The median ETVRR was 71.4% (range, 30 to 
97.6%) and the ETVRR >45% group showed significantly better OS (p < 0.0001) and LRPFS (p = 0.009) than the other group.
Conclusion: ETVRR as a parameter for early treatment response may be a useful prognostic factor to predict treatment outcome 
in LS-SCLC patients treated with CRT.
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Introduction
Small cell lung cancer (SCLC) is a well-known subtype of lung 
cancer that is diagnosed almost exclusively in patients with a 
smoking history [1]. SCLC comprised 13% of new lung cancer 
diagnoses in 2011, and limited stage (LS)-SCLC accounts 
for approximately 30% to 40% of these cases in the United 
States [2]. The current standard treatment for SCLC is systemic 
chemotherapy with concurrent thoracic radiotherapy (RT) for 
consolidation. While this cancer shows favorable response to 
treatment, it still has poor survival outcome [3,4].
Prognostic factors for survival in SCLC include stage, age, 
sex, the World Health Organization performance score, serum 
lactate dehydrogenase level, N3 nodal status, and time from 
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the start of any treatment to the end of radiation therapy 
(SER) [5]. The T stage is a significant prognostic factor for lung 
cancer, but it contains only bi-dimensional measurements of 
gross tumor. The International Commission on Radiation Units 
& Measurements (ICRU) 50 report [6] defines gross tumor 
volume (GTV) as the gross palpable or visible/demonstrable 
extent and location of malignant growth and is the basic 
concept of three-dimensional conformal radiation therapy 
(3DCRT). Initial GTV is a prognostic factor for non-small cell 
lung cancer (NSCLC) patients treated with chemoradiotherapy 
(CRT) [7] and has been studied as an independent prognostic 
factor for survival in SCLC [8].
The volume reduction rate (VRR) during RT is a possible 
indicator of biological tumor radiosensitivity and serves as 
a clinical marker of treatment outcome. In advanced rectal 
cancer patients treated with neoadjuvant CRT, Kim et al. [9] 
revealed a difference in tumor VRR between patients who were 
down-staged by neoadjuvant treatment and those who were 
not. Among head and neck (oropharyngeal or hypopharyngeal) 
cancer patients treated with definitive CRT using intensity-
modulated radiation therapy (IMRT), VRR was a significant 
indicator of local control rate [10]. Werner-Wasik et al. [11] 
investigated the volumetric response of 22 locally-advanced 
NSCLC patients treated with non-surgical therapy including 
thoracic RT. VRR was one of the most effective tools for 
evaluating treatment response.
However, no studies investigate the prognostic effect 
of tumor volume change between initial presentation and 
adaptive RT planning on SCLC survival outcome. The aim of 
the current study is to investigate the relationship between 
treatment response and outcome in patients with LS-SCLC.
Materials and Methods
1. Patients
We retrospectively reviewed the medical records of 106 
patients with SCLC who underwent CRT with definitive aim 
between January 2009 and December 2012. A diagnosis of 
SCLC was confirmed histologically in all patients. SCLC is 
staged by the Veterans Administration Lung Study Group 
(VALSG) staging system [12], according to which patients 
are classified as having limited disease or extensive disease. 
Patients with limited disease have tumor confined to the 
ipsilateral hemithorax, without any malignant effusion, with 
disease that may be incorporated in a single radiation beam 
field. Disease that does not fulfill these criteria is defined as 
extensive disease. Limited/extensive staging was determined 
based on imaging studies, including both diagnostic CT and 
positron emission tomography-computed tomography (PET-
CT). All eligible patients were also staged according to the 7th 
American Joint Committee on Cancer (AJCC) TNM staging 
system [13].
Exclusion criteria included extensive-stage disease (n = 
19), more than one primary cancer that could affect survival 
outcome (n = 6), loss of follow-up after completion of 
treatment (n = 4), incomplete RT less than 45 Gy (n = 3), 
incomplete chemotherapy less than four cycles (n = 13), and 
chemotherapy regimen other than etoposide/cisplatin (EP) or 
etoposide/carboplatin (EC) (n = 14). Finally, 47 patients were 
enrolled in the study.
2. Pretreatment evaluation and follow-up
Pretreatment evaluation included 1) complete history and 
physical examination, 2) biopsy for histological diagnosis, 3) 
laboratory studies, including complete blood cell counts and 
hepatic/renal functions, and 4) imaging studies for staging 
such as chest X-ray, chest CT, brain magnetic resonance 
imaging, and PET-CT. Patients were followed with chest CT and/
or PET-CT one month after radiotherapy, every three months 
within the first year, every six months in the second year, and 
once a year thereafter. Treatment response was evaluated with 
follow-up CT performed one and three months after RT using 
the Response Evaluation Criteria in Solid Tumors (RECIST) ver. 
1.1 guidelines [14].
3. Treatment
1) Chemotherapy: To evaluate changes of tumor volume in 
response to RT evenly, we limited the concurrent chemotherapy 
regimen to only EP (n = 15) or EC (n = 32). The treatment 
schedule was consisted of cisplatin or carboplatin on day 1 
with etoposide on days 1 to 3 for four to six cycles (average 
4.3 cycles), and repeated every three weeks. The standard 
chemotherapy dose was 120 mg/m2 etoposide with 60 mg/m2 
cisplatin for the EP regimen and 100 mg/m2 etoposide for the 
EC regimen. Carboplatin in the EC regimen dose was calculated 
based on the target area under the curve as (5 mg/mL/hr × 
(glomerular filtration rate [GFR] + 25)). GFR was calculated 
with the Cockroft-Gault formula [15]. During treatment, 
six patients required a dose reduction due to hematologic 
toxicities more severe than RTOG grade 1. There was a 
difference in volume between diagnostic CT and planning CT 
because RT started with the second cycle of chemotherapy in 
most patients (n = 35).
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2) Radiotherapy: All patients were treated with 3DCRT. 
Planning CT was performed with contrast and a 3-mm 
thickness for each scan slice. For respiration-dependent organ 
motion, fluoroscopy (Simulix Evolution; Nucletron, Veenendaal, 
the Netherlands) was used in 18 patients prior to July 2010, 
and a 4DCT system (Anzai Medical, Tokyo, Japan) that acquired 
images in 12 phases was used in 29 patients afterward that 
date.
For patients undergoing 2D fluoroscopy, GTV was defined 
as primary tumor and involved regional lymph nodes (LN) 
identified in the planning chest CT. The PET-CT was fused with 
the planning CT for target delineation in all but one patient 
(97.9%). Clinical target volume (CTV) was defined as GTV plus 
a 10 to 15 mm margin in order to include microscopic tumor 
extension. Planning target volume (PTV), for adapting errors 
which could occur through set-up variation and respiratory 
motion, was defined as CTV plus an additional 5 to 15 mm 
margin, depending on 2D fluoroscopy results. For patients 
undergoing 4DCT, GTV was contoured on the mid-ventilation, 
maximum inhalation and exhalation phases in order to reflect 
respiration. CTV was defined as GTV plus a 10 to 15 mm 
margin expansion, and PTV was defined as an additional 5 mm 
margin beyond the CTV.
One patient was treated with IMRT, and 46 patients were 
treated with 3DCRT. Three to five coplanar isocentric fields 
were designed for the initial 3DCRT plan, which used Pinnacle 
radiotherapy treatment planning systems (Philips Radiation 
Oncology Systems, Milpitas, CA, USA) or MIM software ver. 6.3.7 
(MIM Software, Cleveland, OH, USA). An additional simulation 
CT was performed to evaluate GTV shrinkage during RT, and 
adaptive planning focused on accurate tumor targeting and 
preservation of adjacent normal organs (i.e., normal lung 
volume, esophagus). For this adaptive planning, we used a 
larger number of coplanar isocentric beams. In the patient 
treated with IMRT, the RT plan was designed to deliver 56 
Gy to 95% of the PTV using six coplanar MV beams through 
a helical tomotherapy planning system. Definitive CRT was 
followed by prophylactic cranial irradiation (PCI) in patients 
showing complete or partial response.
4. Volumetric parameters
For each patient, we contoured GTVs in four sets of CT images: 
diagnostic, planning, adaptive, and follow-up CT images. 
‘Diagnostic CT’ was defined as the first chest CT that contains 
a malignant lung mass confirmed by a chest radiologist. Chest 
CTs performed at other hospitals were also registered in our 
Picture Archiving and Communication System (PACS) (GE 
Healthcare, Milwaukee, WI, USA) and fused with the ‘planning 
CT’ for target contouring. ‘Adaptive CT’ was defined as a chest 
simulation CT performed at the time of adaptive RT planning, 
using the same setting as the planning CT. ‘Follow-up CT’ 
was conducted for evaluation of the best treatment response 
between one and three months after completion of RT.
When contouring each GTV, we used MIM software ver. 6.3.7 
and homogenized window settings for CT density in order to 
reduce errors. We defined a lung setting with a window of 
1324 and a level of -362 for contouring GTV localized at the 
lung parenchyme and a mediastinum setting with a window of 
500 and a level of 39 for regional LNs.
We proposed overall volume reduction rate (OVRR) as a 
parameter for overall treatment response that appeared as 
percentage change in GTV between diagnostic CT and follow-
up CT. To evaluate early treatment response, we calculated 
early treatment volume reduction rate (ETVRR) as an indication 
of the percentage change in GTV obtained when comparing 
diagnostic CT with adaptive CT. Additionally, we measured 
early chemotherapy volume reduction rate (ECVRR) for pure 
evaluation of first cycle chemotherapy response defined as the 
percentage change in GTV between diagnostic CT and planning 
CT.
5. Statistical analysis
Locoregional progression-free survival (LRPFS), distant metastasis-
free survival (DMFS), progression-free survival (PFS), and overall 
survival (OS) were calculated from the date of diagnosis to the 
event and were plotted using the Kaplan-Meier method. We 
dichotomized patients upon VRR with every 5% interval around 
median to find out most effective cutoff value. For analyzing the 
relationship between the time interval from first chemotherapy 
to first RT and ETVRR, we used the Kruskal-Wallis test. 
Univariate survival analyses for several prognostic factors 
were also processed with the Kaplan-Meier method. To create 
multivariate model, we used stepwise logistic regression with 
variables entry at p < 0.15 and removed if the p-value was 
≥0.15. Patient survival status was confirmed in February 2013. 
In our study, all statistical analyses were performed using SPSS 
ver. 20.0.0 (IBM SPSS, Armonk, NY, USA). A p-value <0.05 was 
considered statistically significant.




The median patient age was 68 years (range, 40 to 84 years), 
and 42 patients (89.4%) were male. At the time of diagnosis, 
41 patients (87.2%) had the Eastern Cooperative Oncology 
Group performance status (ECOG PS) of 0 (n = 12) to 1 (n = 
29). According to the AJCC 7th TNM staging system [13], five 
patients were stage I (10.6%), four patients were stage II (8.5%) 
and 38 patients were stage III (80.9%). The median thoracic 
RT dose was 54 Gy (range, 46 to 64 Gy), with a median daily 
dose of 2 Gy (range, 1.8 to 2.5 Gy). The median time interval 
between diagnostic and planning CT was 32 days (range, 9 to 
123 days). The date of first chemotherapy was a median of 
22 days (range, 0 to 161 days) earlier than the date of first RT. 
Most patients started RT concurrently with 1st (n = 8) or 2nd 
(n = 35) cycle chemotherapy and other four patients received 
delayed RT because of poor general condition status (n = 2) or 
neutropenia caused by initial chemotherapy (n = 2).
Adaptive CT was conducted at a median RT dose of 36 
Gy (range, 28.8 to 43 Gy) and was performed in 30 patients 
(63.9%). After completion of CRT, 38 patients (80.9%) 
underwent PCI. Patient characteristics are provided in Table 1. 
2. Treatment response and pattern of failure
Five patients (10.6%) achieved a complete response, 40 
patients achieved a partial response (85.1%), and two patients 
had stable disease (4.3%). With a median follow-up time of 
27.4 months (range, 6.2 to 66.4 months), the 2-year LRPFS 
and DMFS rates were 74.2% and 70.1%, respectively. Two-
year PFS and OS rates were 50.6% and 56.5%, respectively (Fig. 
1). Of the total patients, 17 (36.2%) experienced locoregional 
failure, 17 (36.2%) had distant failure, and seven (14.9%) had 
both. Sites of distant failure included brain (n = 9), bone (n 
= 2), adrenal gland (n = 2), liver (n = 2), and intra-abdominal 
LNs including the para-aortic area (n = 1). One patient had 
multifocal sites, including the brain, left seventh rib, and LN 
around the celiac trunk.
3. Volumetric parameters related to survival outcome
The volumetric parameters measured in this study are described 
in Table 2. The mean GTV of diagnostic, planning, adaptive, and 
follow-up CT were 117.9 mL (range, 5.9 to 447 mL), 68.7 mL 
(range, 2.5 to 391 mL), 36.8 mL (range, 0.3 to 230.6 mL), and 
20.6 mL (range, 0.1 to 102.1 mL), respectively. Every patient 
experienced volume reduction in each CT when treated with 
CRT. The median OVRR was 81.6% (range, 44.2% to 99%), 
median ECVRR was 53.5% (range, 0% to 82.3%) and the 
median ETVRR of 30 patients with adaptive CT was 71.4% (range, 
30% to 97.6%).
ETVRR was a statistically effective prognostic factor for 
OS (p = 0.012) and PFS (p = 0.015). In the univariate analysis 




   Male
   Female
ECOG PS
   0
   1
   2
T stage
   1–2
   3–4
N stage
   0–2
   3
AJCC stage
   IA
   IB
   IIA
   IIB
   IIIA
   IIIB
Chemotherapy
   Regimen
      Etoposide/carboplatin
      Etoposide/cisplatin
   Cycles
      4
      5
      6
Radiotherapy
   Modality
      3DCRT  
      Tomotherapy
   Dose (Gy)
PCI
   Yes








































Values are presented as median (range) or number of patients (%).
ECOG PS, Eastern Cooperative Oncology Group performance sta-
tus; AJCC, American Joint Committee on Cancer; 3DCRT, three-
dimensional conformal radiation therapy; PCI, prophylactic cranial 
irradiation; SER, start of any treatment to the end of radiation 
therapy.
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with median cutoff value, initial GTV, OVRR, ECVRR, and 
ETVRR showed no prognostic impact on survival outcome (all 
p > 0.05). To reveal most effective cutoff value of VRR, we 
assessed every 5% interval around median. By this process, 
we concluded that ETVRR with 45% cutoff value correlated 
significantly with OS (p < 0.0001) and LRPFS (p = 0.009) (Table 
3). The median OS and LRPFS were 31.3 and 47.5 months for 
patients with greater than 45% ETVRR, respectively, compared 
with 8.3 and 6.3 months for those with a lower than 45% 
value (Fig. 2). Nodal status was a statistically significant 
prognostic factor of DMFS when comparing the N3 group 
versus N0–2 group (p = 0.049). Other factors of age, sex, ECOG 
PS, stage except for nodal status, RT dose, SER, PCI did not 
show statistically significant difference with regard to survival 
outcomes.
Because ETVRR was the only significant prognostic factor 
in the univariate analysis, we assessed the backward stepwise 
multivariate analysis and ETVRR was also shown as the only 
statistically significant factor for OS (HR, 0.117; 95% CI, 0.026 
to 0.530; p = 0.005) and LRPFS (HR, 0.064; 95% CI, 0.007 to 
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Fig. 1. Kaplan-Meier survival curves of 47 patients: (A) overall survival, (B) progression-free survival, (C) locoregional progression-free 
survival and (D) distant metastasis-free survival.
Table 2. Volumetric parameters 
Parameter Value
Gross tumor volume (mL)
   Diagnostic CT (n = 47)
   Planning CT (n = 47)
   Adaptive CT (n = 30)
   Follow-up CT (n = 47)
Volume reduction rate (%)
   Overall
   Early chemotherapy







81.6 ± 13.5 (44.2–99)
53.5 ± 25.9 (0–82.3)
71.4 ± 16.6 (30–97.6)
Values are presented as mean (range) or median ± standard devia-
tion (range).
CT, computed tomography.
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We additionally analyzed the relationship between the 
time interval from first chemotherapy to first RT and ETVRR. 
Patients were divided into three groups depend on the timing 
of RT start. Group 1 (n = 8) and group 2 (n = 35) started RT 
with 1st and 2nd cycle of chemotherapy, and group 3 (n = 4) 
started RT with 3rd or thereafter. Median ETVRR of each group 
was 70.5%, 76.9%, and 66.7%, respectively, and there was no 
statistical difference between the time interval and ETVRR (p = 
0.619).
Table 3. Univariate analysis of prognostic factors
Variable No. 2-yr OS (%) p-value 2-yr PFS (%) p-value 2-yr LRPFS (%) p-value 2-yr DMFS (%) p-value
Age (yr)
   ≤70
   >70
Sex
   Male
   Female
ECOG PS
   <2
   ≥2
T stage
   1–2
   3–4
N stage
   0–2
   3
Stage
   I–IIIA
   IIIB
RT dose (Gy)
   ≤54
   >54
SER (day)
   ≤64
   >64
PCI
   Yes
   No
Initial GTV (mL)
   ≤90
   >90
OVRR (%)
   ≤80
   >80
ECVRR (%)
   ≤50
   >50
ETVRR (%)
   ≤45
































































































































































































































































































































































OS, overall survival; PFS, progression-free survival; LRPFS, locoregional progression-free survival; DMFS, distant metastasis-free survival; 
ECOG PS, Eastern Cooperative Oncology Group performance status; RT, radiotherapy; SER, start of any treatment to the end of radiation 
therapy; PCI, prophylactic cranial irradiation; GTV, gross tumor volume; OVRR, overall volume reduction rate; ECVRR, early chemotherapy 
volume reduction rate; ETVRR, early treatment volume reduction rate.
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Discussion and Conclusion
The aim of this study was to determine prognostic factors 
influencing CRT outcome for LS-SCLC, including tumor volume 
parameters such as OVRR, ECVRR and ETVRR. We hypothesized 
that initial GTV and VRR of gross tumor are prognostic factors 
related to patient survival. The median OVRR was 81.6%, 
showing substantial GTV reduction within three months after 
RT; however, an OVRR >80% was not a statistically significant 
prognostic factor of any survival outcome. The median ETVRR 
was 71.4% (range, 30% to 97.6%), which showed a substantial 
degree of GTV reduction during early CRT, reflecting the 
radiosensitivity of SCLC. An ETVRR >45% was a significant 
prognostic factor of OS (p < 0.0001) and LRPFS (p = 0.009).
Tumor volume defined in CT images is a main concept of 
3DCRT. Before the CT era, the largest longitudinal diameter was 
the only detectable prognostic factor related to tumor size. 
In RTOG 73-01 [16], tumor diameter measurement was based 
on posterior-anterior and lateral chest radiography. With this 
two-dimensional assessment, 91% of patients treated with 
60 Gy showed complete response, partial response or stable 
disease status and only 9% had a progressive response. Such 
favorable outcomes differ considerably from the outcomes of 
more recent studies of lung cancer treatment. To compensate 
for this over-estimation, the definition of CR was changed to 
include radiographic, clinical, and bronchoscopic results [17,18]. 
However, these methods are still less objective than image-
only method due to inter-observer variation. The AJCC TNM 
staging system [13], one of most widely accepted prognostic 
factors of lung cancer, also uses greatest tumor dimension 
based on CT images for T staging.
After the introduction of 3DCRT for cancer treatment, 
physicians began to contour the tumor shape on each planning 
CT slice. Tumor volume was considered as a possible prognostic 
factor based on clinical experiences. Volumetric tumor 
measurement was also considered more objective and accurate 
than clinical evaluation of tumor response.
There have been several studies regarding initial tumor 
volume as a prognostic factor in lung cancer. Bradley et al. 
[19] demonstrated that GTV was a prognostic factor for OS 
and cause-specific survival in NSCLC treated with 3DCRT 
planning. In that study, T, N, and overall stage were not 


































































p < 0.0001 p = 0.009
Table 4. Multivariate logistical regression analyses of prognostic factors
Variable
OS LRPFS
HR (95% CI) p-value HR (95% CI) p-value
Age (>70 yr vs. ≤70 yr)
Sex (male vs. female)
N stage (0–2 vs. 3)

















OS, overall survival; LRPFS, locoregional progression-free survival; HR, hazard ratio; CI, confidence interval; ETVRR, early treatment vol-
ume reduction rate.
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statistically significant prognostic factors. Werner-Wasik 
et al. [20] investigated the efficacy of initial GTV for NSCLC 
patients in the RTOG 93-11 phase I-II trial. In their dose-
escalation study, patients with tumor volume smaller than 45 
cm3 achieved better median survival time and PFS compared 
to those of patients with larger tumors. Basaki et al. [21] also 
showed that primary tumor volume had an impact on OS in 
71 NSCLC stage III patients treated with definitive CRT (n = 
45) or RT alone (n = 26). In that study, GTV and total tumor 
volume were statistically meaningful, but nodal volume alone 
was not. Koo et al. [22] conducted a single-institution study 
that retrospectively reviewed 191 patients with stage III 
NSCLC who underwent CRT. They concluded that smaller pre-
treatment GTV is an independent prognostic factor of better 
OS, PFS, and LRPFS (all p < 0.05). They also studied the impact 
of VRR as a prognostic factor of survival outcome; however, 
it showed only a trend of OS (p = 0.075). Reymen et al. [8] 
revealed total GTV, including gross tumor with selective LNs to 
be irradiated, as an independent prognostic factor of overall 
survival in stage I to III SCLC. This was the first study to show 
the prognostic significance of total GTV in SCLC. Initial GTV 
was not a prognostic factor in this study, and OVRR was also 
not statistically significant. We hypothesize that these results 
are due to the small number of patients and the fact that SCLC 
has a favorable treatment response, as reported in previous 
studies [23], so almost every patient experienced substantial 
volume reduction at follow-up CT.
A limited number of studies have concentrated on the rate 
of 3D volume reduction. VRR was studied in head and neck 
cancer by Yang et al. [10] and was an effective predictor of 
local control in oropharynx and hypopharynx cancer patients 
treated with IMRT. Therefore, it was recommended that 
patients who showed a less than 50% volume reduction should 
be considered for other treatment options like salvage surgery 
or escalated dose prescription. In 2001, Werner-Wasik et al. 
[11] reported that VRR was an effective prognostic factor of 
response evaluation in locally-advanced NSCLC patients. Since 
then, however, no studies have produced meaningful results 
regarding volume changes in lung cancer. This study was the 
first attempt to reveal the prognostic importance of VRR in 
SCLC.
The ETVRR <45% group patients showed poor OS and LRPFS 
(8.3 and 6.3 months, respectively) and this was relatively 
poor survival outcome than previous studies. The reason 
was because of early locoregional failure in ipsilateral lung 
parenchyme (n = 2) and brain metastasis (n = 1).
This study has some limitations. Established prognostic 
factors in SCLC (age, sex, ECOG PS, SER, initial GTV, and 
overall treatment response) were not significantly correlated 
with survival outcome in this study, which may have been 
influenced by the relatively small number of patients included 
in analysis. Not all patients were subjected to adaptive 
planning, and ETVRR was determined in only 30 of 47 
patients. Currently, most SCLC patients treated with CRT at our 
institution undergo adaptive planning; a longer follow-up with 
a larger number of patients will reveal the validity of these 
results.
In conclusion, overall and early treatment responses to 
chemo-radiation in LS-SCLC as measured by volume reduction 
were favorable. Patients who showed an early treatment 
response (ETVRR >45%) had better treatment outcome in 
terms of PFS and OS than those who did not. ETVRR as a 
parameter for early treatment response may be a useful 
prognostic factor of treatment outcome in LS-SCLC patients 
treated with CRT. 
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